Asthma is a chronic inflammatory disease of the airways that has become increasingly prevalent worldwide over the past few decades. Characterized by recurrent attacks of breathlessness and wheezing, asthma affects nearly 300 million people globally and imposes a significant burden on both individual patients and public health systems. While its underlying pathophysiology is complex and incompletely understood, asthma is recognized as a heterogeneous condition arising from interplay between genetic and environmental factors in the context of allergen and irritant exposures. Considerable progress has been made over the past half century in elucidating the mechanisms of asthma, identifying risk factors, developing improved treatment options, and lessening the associated morbidity and mortality. Asthma continues to present numerous unresolved questions that warrant ongoing investigation to advance prevention and management strategies.
The purpose of this paper is to review current knowledge and research directions in key areas of asthma pathobiology and epidemiology. We will begin by briefly discussing the definition and clinical presentation of asthma, focusing on symptoms that characterize the variable airway obstruction and inflammation that are hallmarks of the disease. Next, we will examine genetic and environmental risk factors thought to influence asthma development and severity. A major section will be dedicated to exploring the complex inflammatory pathways involved in asthma, noting both immune and structural cells as well as various mediators implicated in the pathogenesis of recurrent airway narrowing and remodeling. We will then consider recent findings regarding potential asthma phenotypes and endotypes aimed at improving disease classification. Another section will review clinical and public health efforts to better control asthma, including pharmacological therapy guidelines, challenges with adherence, self-management strategies, and population-level interventions.
Finally, we will conclude by highlighting important unanswered questions and promising avenues for future asthma research. Areas of particular interest that warrant continued exploration include elucidating the multifaceted gene-environment interactions driving disease risks, discerning molecular mechanisms linking asthma triggers to airway processes, characterizing novel cellular and molecular subsets distinguishing different asthma subtypes, leveraging big data approaches to optimize precision medicine, developing non-pharmacological complementary and alternative therapies, and expanding international collaborative efforts to curb the global asthma epidemic. By summarizing current understandings and identifying gaps in knowledge, this paper aims to provide context for ongoing work toward developing more targeted and effective strategies to prevent, diagnose, and treat this prevalent chronic respiratory disorder.
Asthma is clinically defined as a heterogeneous disease characterized by chronic airway inflammation, variable symptoms such as wheezing, breathlessness, chest tightness and cough, and reversible airflow limitation or obstruction. These symptoms are generally due to a combination of airway smooth muscle contraction, bronchial edema and thickening of the airways caused by inflammation and excessive mucus production. Symptoms can range from intermittent and mild to severe and persistent and may vary over time for individual patients. The variable airflow limitation is due to bronchoconstriction, oedema of the airway walls, increased mucus secretion and airway remodeling. Symptoms arise as a result of complex interactions between underlying genetic factors and environmental exposures that trigger inflammatory responses in vulnerable individuals (Global Initiative for Asthma, 2020).
Airway inflammation is recognized as a key pathogenic driver in asthma, involving numerous interacting immune and structural cells as well as diverse mediators. Innate lymphoid cells, mast cells, eosinophils, neutrophils, and macrophages infiltrate the asthmatic airways, playing roles in both initiating and sustaining the inflammatory response through release of cytokines, chemokines, lipid mediators, reactive oxygen species, and proteases. Adaptive immune T helper type 2 (Th2) and Th17 cells coordinated by CD4+ lymphocytes promote and amplify inflammation via secretion of Th2 cytokines such as IL-4, IL-5, IL-9, and IL-13 which stimulate IgE production, eosinophil recruitment, goblet cell hyperplasia, and hypercontractility of bronchial smooth muscle cells. Repeated inflammation ultimately results in structural changes to the airway termed remodeling, characterized by subepithelial thickening, myofibroblast proliferation, and fibrosis. The complex interplay between different cell types and mediators in a dynamic process creates a challenging environment for asthma management.
A wealth of evidence indicates asthma is influenced by both genetic and environmental components interacting in a context-dependent manner. Family and twin studies have established heritability estimates for asthma of 30-80%, with over 100 candidate genes implicated in disease susceptibility based on genome-wide association studies. No single gene variants confer large effects, reflecting the polygenic nature of asthma with numerous genes of small influence interacting in networks. Environmental exposures likely modulate disease expression through epigenetic modifications and gene-environment interactions involving airborne particles, gases, allergens, tobacco smoke, air pollution, drugs, respiratory viruses, diet, microbiota and lifestyle factors. Exposure timing, dose, and individual susceptibility appear important in determining ultimate asthma risk and phenotypes. Better elucidating gene-environment interactions holds promise for understanding asthma pathogenesis and preventive strategies.
In recent decades, emphasis has grown on classifying clinically and pathophysiologically distinct asthma subtypes or endotypes to enable more specific diagnosis and personalized treatment. Phenotypes based on age of onset, severity, symptom patterns, comorbidities, sensitization profiles, and lung function behaviors are useful for guiding management of different patient groups, but may not fully capture underlying mechanisms. Molecular endotypes defined by pathogenic processes, cellular profiles, biomarkers and underlying genetic architectures potentially offer a more precise approach for directing tailored therapies. Ongoing endotyping research incorporating omics technologies, advanced imaging modalities, longitudinal patient monitoring and artificial intelligence holds promise to revolutionize asthma stratification. Significant challenges remain to efficiently translate findings into clinical practice due to complexity, cost and limited biomarkers.
Despite evidence-based treatment guidelines emphasizing longitudinal control through environmental control measures, pharmacotherapy and patient education, global asthma burden remains high. Persistent symptoms, risk of exacerbations and comorbidities in many populations highlight the need for improved control strategies. Adherence to long-term controller medications proven to reduce symptoms and prevent progression represents a major barrier, with contributing factors including cost, adverse effects, patients’ cognitive biases, lack of perceived benefit, dissatisfaction with care process and healthcare system weaknesses. Self-management empowering patients through action plans, monitoring, inhaler technique training and guideline-driven follow-up shows promise but requires resources and reinforcement. Population health measures addressing regional environmental risks could also positively impact disease control if implemented comprehensively.
Overall, significant progress has occurred in asthma epidemiology, pathobiology and treatment over recent decades. Numerous outstanding questions warrant ongoing investigation to advance management strategies: How do genetic, epigenetic and environmental factors interact to initiate disease and determine progression risks? What underlying cellular and molecular mechanisms link asthma triggers with the observed temporal patterns of inflammation, remodeling, and clinical course? How can endotypes best be defined and targeted with precision medicine approaches? How may non-pharmacological complementary and alternative therapies strengthen control? What innovative partnerships across disciplines and borders will most effectively curb the still-rising global asthma burden? Answering these questions will require continued collaborative efforts leveraging convergent multiomic technologies, big data analytics, and innovative clinical trial designs. With ongoing research addressing remaining knowledge gaps, more personalized and effective prevention strategies are envisioned for the heterogeneous disorder of asthma.
This paper aimed to provide a comprehensive overview of key topics relevant to current asthma research by outlining clinical definitions, reviewing risk factors, exploring inflammatory pathways, discussing efforts toward improved classification, considering challenges with disease control, and highlighting important unanswered scientific questions. Through contextualizing current understandings and identifying knowledge gaps, it is hoped this introduction will help set the stage for more targeted investigation advancing personalized, preventive and management approaches for the complex chronic condition of asthma impacting over 300 million individuals worldwide. Significant progress continues to be made through collaborative global efforts across disciplines; Asthma will remain an active area for future research seeking to optimize precision strategies, maximally mitigate disease burden through non-pharmacological interventions, better elucidate pathogenic mechanisms, and ultimately curb the rising global asthma epidemic.
Andrew Stroud